Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 ФГБУ НИИ фармакологии им. В.В.Закусова РАМН, Москва 2 Кафедра психиатрии ФУВ РНИМУ им. Н.И.Пирогова, Москва
Список исп. литературыСкрыть список 1. Pollack MH, Otto MW, Roy-Byrne PP et al. Novel treatment approaches for refractory anxiety disorders. Depress Anxiety 2008; 25 (6): 467–76. 2. Середенин С.Б., Воронина Т.А., Незнамов Г.Г., Жердев В.П. Феназепам: 25 лет в медицинской практике. М.: Наука, 2007. 3. Авруцкий Г.Я., Недува А. Лечение психически больных. Руководство для врачей. А.: Медицина, 1988. 4. Незнамов Г.Г., Сюняков С.А., Чумаков Д.В. и др. Результаты клинического изучения селективного анксиолитика Афобазола. Эксперим. и клин. фармакология. 2001; 64 (2): 15–9. 5. Сюняков С.А., Гришин С.А., Телешова Е.С. и др. Результаты пилотного клинического исследования Ладастена. Эксперим. и клин. фармакология. 2006; 69 (4): 10–5. 6. Незнамов Г.Г., Телешова Е.С., Бочкарев В.К. Результаты клинико-фармакологических исследований пептидного препарата Селанка в качестве анксиолитического средства. Терапия психич. заболеваний. 2002; с. 28–36. 7. Незнамов Г.Г., Сюняков С.А., Телешева Е.С. Терапевтическое действие и эффективность феварина (флувоксамина) у больных с непсихотическими тревожными и апатоадинамическими депрессиями. Журн. неврол. и психиатр. им. С.С.Корсакова. 2001; 8 (19): 24. 8. Незнамов Г.Г., Телешова Е.С., Сюняков С.А., Сафарова Т.П. Клинико-фармакологическое исследование анксиолитических свойств антиоксиданта мексидола. Материалы симпозиума «Медицина и охрана здоровья. Медтехника и аптека». Тюмень, 1997; с. 85–7. 9. Сюняков С.А., Незнамов Г.Г., Телешова Е.С. Терапевтическое действие и эффективность рисполепта (рисперидона) у больных малопрогредиентной шизофренией. Соц. и клин. психиатрия. 2003; 13 (2): 125–32. 10. Незнамов Г.Г., Сюняков С.А., Чумаков Д.В., Маметова Л.Э. Новый селективный анксиолитик Афобазол. Журн. неврол. и психиатр. 2005; 105 (4): 35–40. 11. Незнамов Г.Г., Сюняков С.А., Чумаков Д.В. и др. Новый анксиолитик Афобазол: результаты сравнительного клинического исследования с диазепамом при генерализованном тревожном расстройстве. Психиатр. и психофармакотер. 2006; 4: 8–15. 12. Зозуля А.А., Незнамов Г.Г., Сюняков Т.С. и др. Эффективность и возможные механизмы действия нового пептидного анксиолитика селанка при терапии генерализованного тревожного расстройства и неврастении. Журн. неврол. и психиатр. им. C.C.Корсакова. 2008; 108 (4): 38–48. 13. Дорофеева О.А., Сюняков С.А., Жердев В.П. и др. Особенности терапевтического действия и фармакокинетики феназепама в трансдермальной лекарственной форме у больных с тревожными расстройствами. Эксперим. и клин. фармакология. 2009; 72 (2): 6–10. 14. Незнамов Г.Г., Сюняков С.А., Телешова Е.С. и др. Новый препарат со стимулирующими и анксиолитическими свойствами ладастен при лечении неврастении (результаты сравнительного клинического исследования с плацебо). Журн. неврол. и психиатр. им. С.С.Корсакова. 2009; 109 (5): 20. 15. Bandelow B, Zohar J, Hollander E et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. World J Biol Psychiat 2008; 9 (4): 248–312. 16. Borkovec TD, Shadick R, Hopkins M. The nature of normal and pathological worry. Chronic anxiety, generalized anxiety disorder, and mixed anxiety depression. Ed.: R.Rapee, D.Barlow. NY: Guilford 1991; p. 29–51. 17. Craske MG, Rapee RM, Jackel L et al. Qualitative dimensions of worry in DSM-IIIR generalized anxiety disorder subjects and nonanxious controls. Behav Research Therapy 1989; 27: 397–402. 18. Roemer L, Molina S, Borkovec TD. An investigation of worry content among generally anxious individuals. J Nerv Ment Dis 1997; 185 (5): 314–9. 19. Brown TA, Barlow DH, Liebowitz MR. The empirical basis of generalized anxiety disorder. Am J Psychiat 1994; 151 (9): 1272–80. 20. Davey GC, Levy S. Catastrophic worrying: personal inadequacy and a perseverative iterative style as features of the catastrophizing process. J Abnorm Psychol 1998; 107 (4): 576–86. 21. Boden JM, Fergusson DM, John Horwood L. Anxiety disorders and suicidal behaviours in adolescence and young adulthood: findings from a longitudinal study. Psycholog Med 2007; 37 (3): 431–40. 22. Starcevic V, Bogojevic G. The concept of generalized anxiety disorder: between the too narrow and too wide diagnostic criteria. Psychopathol 1999; 32: 5–11. 23. Feltner DE, Crockatt JG, Dubovsky SJ et al. A randomized double-blind placebo-controlled fixed-dose multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 2003; 23 (3): 240–9. 24. Kasper S, Herman B, Nivoli G et al. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind placebo-controlled 8-week trial. Int Clin Psychopharmacol 2009; 24 (2): 87–96. 25. Montgomery S, Chatamra K, Pauer L et al. Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiat 2008; 193 (5): 389–94. 26. Montgomery SA, Tobias K, Zornberg GL et al. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week multicenter randomized double-blind placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiat 2006; 67 (5): 771–82. 27. Pande AC, Crockatt JG, Feltner DE et al. Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiat 2003; 160 (3): 533–40. 28. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind placebo-controlled comparison of BID vs TID dosing. J Clin Psychopharmacol 2005; 25 (2): 151–8. 29. Rickels K, Pollack MH, Feltner DE et al. Pregabalin for treatment of generalized anxiety disorder: a 4-week multicenter double-blind placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiat 2005; 62 (9): 1022–30. 30. Feltner D, Wittchen HU, Kavoussi R et al. Long-term efficacy of pregabalin in generalized anxiety disorder. Int Clin Psychopharmacol 2008; 23 (1): 18–28. 31. Hadley SJ, Mandel FS, Schweizer E. Switching from long-term benzodiazepine therapy to pregabalin in patients with generalized anxiety disorder: a double-blind placebo-controlled trial. J Psychopharmacol 2012; 26 (4): 461–70. 32. Bech P. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials. Pharmacopsychiat 2007; 40 (4): 163–8. 33. Lydiard RB, Rickels K, Herman B, Feltner DE. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder. Int J Neuropsychopharmacol 2010; 13 (2): 229–41. 34. Meoni P, Salinas E, Brault Y, Hackett D. Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiat 2001; 62 (11): 888–93. 35. Nutt D, Mandel F, Baldinetti F. Early onset anxiolytic efficacy after a single dose of pregabalin: double-blind placebo- and active-comparator controlled evaluation using a dental anxiety model. J Psychopharmacol 2009; 23 (8): 867–73. 36. Gonano C, Latzke D, Sabeti-Aschraf M et al. The anxiolytic effect of pregabalin in outpatients undergoing minor orthopaedic surgery. J Psychopharmacol 2011; 25 (2): 249–53. 37. Bollu V, Bushmakin AG, Cappelleri JC et al. Pregabalin reduces sleep disturbance in patients with generalized anxiety disorder via both direct and indirect mechanisms. Europ J Psychiat 2010; 24: 18–27. 38. Holsboer-Trachsler E, Prieto R. Effects of pregabalin on sleep in generalized anxiety disorder. Int J Neuropsychopharmacol 2012; 1–12. 39. Sabatowski R, Galvez R, Cherry DA et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomized placebo-controlled clinical trial. Pain 2004; 109 (1–2): 26–35. 40. Saldana MT, Navarro A, Perez C et al. Patient-reported-outcomes in subjects with painful lumbar or cervical radiculopathy treated with pregabalin: evidence from medical practice in primary care settings. Rheumatol Int 2010; 30 (8): 1005–15. 41. Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005; 28 (2): 187–93. 42. Kubota T, Fang J, Meltzer LT et al. Pregabalin enhances nonrapid eye movement sleep. J Pharmacol Exp Ther 2001; 299 (3): 1095–105. 43. Roth T, Lankford DA, Bhadra P et al. Effect of pregabalin on sleep in patients with fibromyalgia and sleep maintenance disturbance: a randomized placebo-controlled 2-way crossover polysomnography study. Arthritis Care Res Hoboken 2012; 64 (4): 597–606. 44. Bazil CW, Dave J, Cole J et al. Pregabalin increases slow-wave sleep and may improve attention in patients with partial epilepsy and insomnia. Epilepsy Behav 2012; 23 (4): 422–5. 45. Stein DJ, Baldwin DS, Baldinetti F, Mandel F. Efficacy of pregabalin in depressive symptoms associated with generalized anxiety disorder: a pooled analysis of 6 studies. Eur Neuropsychopharmacol 2008; 18 (6): 422–30. 46. Zelman DC, Gore M, Dukes E et al. Validation of a modified version of the brief pain inventory for painful diabetic peripheral neuropathy. J Pain Symptom Manage 2005; 29 (4): 401–10. 47. Arnold LM, Crofford LJ, Martin SA et al. The effect of anxiety and depression on improvements in pain in a randomized, controlled trial of pregabalin for treatment of fibromyalgia. Pain Med 2007; 8 (8): 633–8. 48. Crofford LJ, Rowbotham MC, Mease PJ et al. Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized double-blind placebo-controlled trial. Arthritis Rheum 2005; 52 (4): 1264–73. 49. Mease PJ, Russell IJ, Arnold LM et al. A randomized double-blind placebo-controlled phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol 2008; 35 (3): 502–14. 50. Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with gabapentin and pregabalin – a meta-analysis of randomized controlled trials. Pain 2009; 145 (1–2): 69–81. 51. Straube S, Derry S, Moore RA, McQuay HJ. Pregabalin in fibromyalgia: meta-analysis of efficacy and safety from company clinical trial reports. Rheumatol Oxford 2010; 49 (4): 706–15. 52. Hindmarch I, Trick L, Ridout F. A double-blind placebo- and positive-internal-controlled (alprazolam) investigation of the cognitive and psychomotor profile of pregabalin in healthy volunteers. Psychopharmacol Berl 2005; 183 (2): 133–43. 53. Zaccara G, Perucca P, Gangemi PF. The adverse event profile of pregabalin across different disorders: a meta-analysis. Eur J Clin Pharmacol 2012; 68 (6): 903–12.